Other News To Note

Threshold Pharmaceuticals Inc., of Redwood City, Calif., said the National Comprehensive Cancer Network awarded a grant to Herb Hurwitz, associate professor of medicine at the Duke Cancer Institute, to evaluate the company's hypoxia-activated prodrug, TH-302. The Duke Cancer Institute expects to begin a Phase I trial during the fourth quarter to evaluate the safety and preliminary activity of TH-302 in combination with pazopanib (Votrient) in advanced solid tumors. In March, the company raised $30 million in a registered direct offering to advance clinical trials for TH-302.